David-Alexandre Gros

David-Alexandre C.
Gros was the founder of Climb Bio, Inc., founded in 2018, where the title held was Director from 2018 to 2020.
Dr. Gros was the founder of Imbria Pharmaceuticals, Inc., founded in 2018, where the title held was Chairman & Chief Executive Officer from 2018 to 2020.
The current job is Chief Executive Officer & Director at Eledon Pharmaceuticals, Inc. starting in 2020.
Former jobs include President, Chief Operating & Financial Officer at Neurocrine Biosciences, Inc. in 2017; Chief Strategy Officer & Executive Vice President at Sanofi from 2013 to 2015; Associate Principal at McKinsey & Co., Inc. from 2002 to 2006; Chief Financial Officer at Alnylam Pharmaceuticals, Inc. from 2016 to 2017; Member-Supervisory Board at Saint Jean Groupe SA from 2014 to 2015; Principal at Centerview Partners LLC from 2009 to 2011; and Chief Strategy Officer at Sanofi from 2011 to 2015.
Education includes an undergraduate degree from Dartmouth College in 1995, a doctorate from The Johns Hopkins University School of Medicine in 1999, and an MBA from Harvard Business School in 2002.